BackHTG Molecular Diagnostics Overview

HTG Molecular Diagnostics Long Term Debt

Track HTG Molecular Diagnostics's long-term debt ($420K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$423237.00
89.54% YoYΔ $-3.62M vs prior year quarter

Peer average

Loading

HTG Molecular Diagnostics Long Term Debt History

Loading

HTG Molecular Diagnostics vs. peers: Long Term Debt Comparison

Loading

HTG Molecular Diagnostics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

HTG Molecular Diagnostics (HTGM) FAQ

As of the most recent data (March 2023), HTGM shows a long-term debt of $420K. That compares with $4M in the prior-year period — down 89.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, HTGM's long-term debt is now $420K (was $4M) — a 89.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether HTG Molecular Diagnostics is outperforming or lagging.

Tracking HTGM's long-term debt over time shows whether HTG Molecular Diagnostics is scaling, shrinking, or reshaping that part of the business. The current reading is $420K That compares with $4M in the prior-year period — down 89.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has HTG Molecular Diagnostics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $420K) with ownership activity and broader fundamentals.

HTG Molecular Diagnostics's long-term debt is $420K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.